Genfit SA

Genfit SA(GNFT)股票分析

$4.850

+0.123 (+2.54%)收盘时

Loading chart…
High
4.929
Open
4.380
VWAP
4.72
Vol
56.95K
Mkt Cap
192.46M
Low
4.372
Amount
268.63K
EV/EBITDA, TTM
61.82

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

www.genfit.fr

估值指标

The current forward P/E ratio for Genfit SA (GNFT) is -3.81, compared to its 5-year average forward P/E of 6.75.

Forward P/E

Fair
5Y Average P/E
6.75
Current P/E
-3.81
高估
60.99
低估
-47.50

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
2.10
Current EV/EBITDA
61.82
高估
16.88
低估
-12.68

Forward P/S

Fair
5Y Average P/S
3.90
Current P/S
1.63
高估
6.46
低估
1.35

GNFT FAQ — answered by Alphio AI

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making. It operates in the Healthcare sector.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始